Cullen/Frost Bankers’s Pacira BioSciences PCRX Stock Holding History

Cullen/Frost Bankers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500	Closed	-$15.3K	–	1143
2023 Q3	$15.3K	Hold	500	–	–	﹤0.01%	888
2023 Q2	$20K	Hold	500	–	–	﹤0.01%	856
2023 Q1	$20.4K	Hold	500	–	–	﹤0.01%	860
2022 Q4	$19.3K	Hold	500	–	–	﹤0.01%	846
2022 Q3	$27K	Hold	500	–	–	﹤0.01%	810
2022 Q2	$29K	Hold	500	–	–	﹤0.01%	789
2022 Q1	$38K	Hold	500	–	–	﹤0.01%	786
2021 Q4	$30K	Hold	500	–	–	﹤0.01%	844
2021 Q3	$28K	Hold	500	–	–	﹤0.01%	904
2021 Q2	$30K	Hold	500	–	–	﹤0.01%	903
2021 Q1	$35K	Hold	500	–	–	﹤0.01%	784
2020 Q4	$30K	Hold	500	–	–	﹤0.01%	791
2020 Q3	$30K	Hold	500	–	–	﹤0.01%	764
2020 Q2	$26K	Hold	500	–	–	﹤0.01%	765
2020 Q1	$17K	Hold	500	–	–	﹤0.01%	663
2019 Q4	$23K	Hold	500	–	–	﹤0.01%	766
2019 Q3	$19K	Hold	500	–	–	﹤0.01%	735
2019 Q2	$22K	Hold	500	–	–	﹤0.01%	683
2019 Q1	$19K	Buy	+500	New	+$19.5K	﹤0.01%	685
2014 Q4	–	Sell	-2,200	Closed	-$213K	–	395
2014 Q3	$213K	Buy	+2,200	New	+$214K	0.01%	365

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Cullen/Frost Bankers's PCRX Position: Q4 2023 in Review

Cullen/Frost Bankers sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 500 shares — an estimated $15.3K sold.

Cullen/Frost Bankers first reported a position in PCRX in Q3 2014 and held it in 20 quarters. The position peaked at $213K in Q3 2014. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Cullen/Frost Bankers reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Cullen/Frost Bankers sold 500 Pacira BioSciences shares in Q4 2023, an estimated $15.3K.
Cullen/Frost Bankers first reported a position in Pacira BioSciences in Q3 2014 and held it in 20 quarters.
Cullen/Frost Bankers's Pacira BioSciences position peaked at $213K in Q3 2014.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Cullen/Frost Bankers's 13F filing for Q4 2023, filed 6 Feb 2024.